Novo Nordisk A/S
Stocks making the biggest moves midday: Novo Nordisk, Vistra, GE Vernova, Regions Financial and more
Check out some of the companies making headlines in midday trading: Novo Nordisk — The maker of the Wegovy obesity treatment jumped more than 4% as sales of its oral weight loss treatment got off to a strong start. In the first week of its launch, about 1.3% of Wegovy prescriptions were for the oral […]
Read More
Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid’ launch
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, US, on Thursday, Jan. 15, 2026. George Frey | Bloomberg | Getty Images Shares of Novo Nordisk rose more than 5% on Friday after early prescription data showed an encouraging start to the U.S. launch of the company’s new GLP-1 pill […]
Read More
This pharma stock just got whacked — there’s still a major catalyst ahead
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Stocks were climbing on Thursday led by semiconductors and AI-related names. Taiwan Semiconductor rallied more than 5% after reporting strong fourth quarter results and forecasting higher […]
Read More
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good morning from San Francisco! It’s day three of the annual JPMorgan Healthcare Conference – the biggest gathering of biotech and pharma execs, investors and analysts in […]
Read More
Powell’s criminal investigation, Google’s AI shopping push, Boeing deliveries and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Monday. I find myself at an impasse trying to decide what to write in this intro. As someone who’s committed to their skincare routine, I should write about this story on the latest men’s beauty trend. But as a Michigan native, […]
Read More
Behind Anthropic’s stunning growth is a sibling team that may hold the key to generative AI
SAN FRANCISCO — Daniela Amodei has an energy that’s hard to place — warm, unhurried, immediately present. She swept into a sunlit room on the ground floor of Anthropic’s headquarters in December, sat down, and immediately apologized for her mug. “Is my, like, gigantic novelty mug going to be distracting if I have it?” she […]
Read More
2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market
The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy. […]
Read More
Healthy Returns: What to expect from pharma at the JPM conference
Heidi Overton, Novo Nordisk CEO Maziar Mike Doustdar, Eli Lilly CEO David A. Ricks, and U.S. Secretary of Commerce Howard Lutnick listen while U.S. President Donald Trump announces a deal with Eli Lilly and Novo Nordisk on to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White […]
Read More
Amazon Pharmacy starts offering Novo Nordisk’s Wegovy weight-loss pill
Close-up of a hand holding a cellphone displaying the Amazon Pharmacy system, Lafayette, California, September 15, 2021. Smith Collection | Gado | Getty Images Amazon announced Friday it now offers Novo Nordisk‘s Wegovy weight-loss pill through its digital pharmacy. Novo Nordisk began rolling out an oral version of its injectable obesity drug Wegovy in the […]
Read More
A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year
Europe’s best-performing blue-chip stock in 2025 is widely expected to be bought by a larger peer, in a deal analysts say could be worth as much as $23 billion. Abivax, the French clinical-stage biotech company developing a treatment for ulcerative colitis and Crohn’s disease, saw shares rocket 1,681% last year, far outpacing the Stoxx 600 […]
Read More